Edwards outlines ~11.5% 2026 sales growth and $2.97-$3.05 adjusted EPS, supported by TAVR and TMTT momentum

Edwards Lifesciences Q3 2026 earnings: sales beat, raised guidance, stronger TAVR and TMTT growth.

CryptoAlerta — análise de criptomoedas e mercado em tempo real